Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

NCT07554495 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Polyarticular Course Juvenile Idiopathic Arthritis

Interventions

DRUG: Filgotinib

Sponsor

Alfasigma S.p.A.